Open AccessTelaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients
Author(s) -
Delphine Bonnet,
Matthieu Guivarch,
Émilie Bérard,
JeanMarc Combis,
Andre Jean Remy,
André Glibert,
JeanLouis Payen,
Sophie Métivier,
Karl Barange,
Hervé Desmorat,
Anaïs Palacin,
Florence Nicot,
Florence Abravanel,
Laurent Alric
Publication year - 2014
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v6.i9.660
Subject(s) - boceprevir , medicine , telaprevir , ribavirin , gastroenterology , liver biopsy , hepatitis c virus , pegylated interferon , hepatitis c , immunology , biopsy , virus
To assess, in a routine practice setting, the sustained virologic response (SVR) to telaprevir (TPV) or boceprevir (BOC) in hepatitis C virus (HCV) null-responders or relapsers with severe liver fibrosis.